New Engager Spotlights
Myriad Genetics Engager
Tuesday, February 3, 2026 | 9:30-11:30
Ahead of next week, take an exclusive look at the agenda breakdown of Myriad Genetics' Engager Session. Look forward to participating in interactive discussions revolving around the real-world application of MRD data in patient management, trial design, and therapeutic development.
Personalis Engager
Tuesday, February 3, 2026 | 12:00-2:30
Download a PDF copy outlining the agenda of Personalis' Engager Session, taking place on Tuesday. Hear directly from industry leaders on the role of MRD in accelerating clinical developments to make meaningful adaptations to your current workflows.
Natera Engager
Tuesday, February 3, 2026 | 3:00-5:30
Access a preview of the agenda set to take place at Natera's Engager Session. In your copy, find the complete details on the experts sharing data from Foresight’s phased-variant technology, that has been recently integrated into their Signatera™ platform.
Guardant Engager
Tuesday, February 3, 2026 | 6:00-8:30
Get prepared for the 10th Liquid Biopsy for Precision Oncology Summit by accessing your copy of the program for Guardant Health's Engager Session. Inside find out how biopharma researchers and clinical oncologists are using novel biomarkers to bring more effective therapies to patients in need.
Hear From:
Steffan Ho M.D., Vice President & Head, Translational Oncology, Pfizer
Zoe June Assaf, Senior Director, Cancer Genomics & Emerging Technologies, Revolution Medicines
Justin Odegaard, Senior Vice President, Product Management, Guardant Health
Jean-Francois Martini, Sr Director, Translational strategy, Guardant Health
Ben Herzberg, Assistant Professor, Medicine, Columbia University Irving Medical Center
Foundation Medicine Engager
Wednesday, February 4, 2026 | 7:05-9:10
Sneak a peek at the discussions, experts and perspectives you can expect at Foundation Medicine's Engager Session. Gain an exclusive look at the next generation biomarkers driving smarter clinical trial enrolment and monitoring.
Discover the Event Program
See where leading teams at AstraZeneca, Amgen, Pfizer and Johnson & Johnson are taking ctDNA next, from dose finding through to MRD endpoints.
Prioritize Partnering With Us
Place your liquid biopsy platform in front of the pharma teams choosing assay partners for their next trials, before the vendor landscape settles.
Join 250+ Biopharma Peers
Meet the translational and precision medicine experts shaping future liquid biopsy strategies, so you can return to your team with actionable plans to implement in 2027 and beyond.